ParenteralDosed ingredient Cosmetic cross-reference

Biotin

CAS 58-85-5

Biotin (CAS 58-85-5) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 3,120 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
6
SOURCE DrugCentral
Adverse signals
3,120
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Biotin
CAS Number
58-85-5
UNII
6SO6U10H04
InChIKey
YBJHBAHKTGYVGT-ZKWXMUAHSA-N
ChEMBL ID
CHEMBL857
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
D-biotin
dosed ingredientnatural productparenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL857 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 6 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 12514.606153846154 nM 65 -
- Potency 12343.017142857143 nM 28 -
- IC50 55864.64538461539 nM 11 -
- EC50 2318.6666666666665 nM 3 -
- Kd 6000 nM 1 -
Insulin-degrading enzyme
Enzyme
 EC50 5.6 - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Fractional exhaled nitric oxide increased 57 208.423 10078429
Toxicity to various agents 16 137.905 10070863
Myoglobin blood increased 57 137.035 10028625
Fatigue 952 134.647 10016256
Presbyacusis 52 132.512 10036626
Pleural thickening 53 130.538 10035616
Plantar fasciitis 60 129.82 10035155
Blood magnesium increased 53 122.147 10005655
Sensation of foreign body 62 121.892 10061549
Pleural fibrosis 53 112.671 10035600
Alopecia 367 97.902 10001760
Deafness neurosensory 55 95.871 10011891
Epigastric discomfort 56 93.483 10053155
Brain natriuretic peptide increased 57 91.842 10053405
Exostosis 77 91.11 10015688
Muscle spasms 254 90.791 10028334
Product dose omission issue 334 89.652 10084406
Dry eye 107 85.904 10013774
Acute kidney injury 69 85.692 10069339
Cyst 67 81.271 10011732
Secretion discharge 64 78.829 10053459
Appendicolith 47 77.204 10074458
Synovitis 3 76.973 10042868
Completed suicide 8 72.016 10010144
Drug interaction 54 70.204 10013710
Stress 137 70.132 10042209
Headache 591 69.582 10019211
Dysphonia 113 68.168 10013952
Osteopenia 67 67.27 10049088
Hand deformity 3 62.645 10061194
Drug abuse 3 57.615 10013654
COVID-19 197 56.841 10084268
Multiple sclerosis relapse 90 52.718 10048393
Abdominal distension 155 51.578 10000060
Onychoclasis 35 49.516 10048886
Nasopharyngitis 273 49.057 10028810
Glossodynia 12 48.87 10018388
Constipation 288 48.361 10010774
Blood potassium increased 66 48.352 10005725
Maternal exposure during pregnancy 20 47.745 10071408
Memory impairment 150 47.046 10027175
Blood phosphorus increased 38 46.6 10050196
Dry mouth 126 46.513 10013781
Sinusitis 230 46.457 10040753
Systemic lupus erythematosus 20 46.135 10042945
Contraindicated product administered 28 44.914 10078504
Febrile neutropenia 28 44.56 10016288
Skin lesion 80 44.044 10040882
Osteosclerosis 28 42.852 10031298
Diarrhoea 673 42.551 10012735

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Biotin 1588 SU MTHSPL
BIOTIN 1588 SU MTHSPL
biotin 1588 IN RXNORM
D-biotin 314583 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Biotin used for in pharmaceutical contexts?

Biotin (CAS 58-85-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Biotin?

Biotin has 3,120 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Fractional exhaled nitric oxide increased, Toxicity to various agents, Myoglobin blood increased, Fatigue, Presbyacusis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Biotin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Biotin with EU status "permitted".

What clinical phase is Biotin in?

Biotin is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Biotin?

Biotin has 6 bioactivity rows in this page query. Rendered target entries include Insulin-degrading enzyme.